Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Glargine insulin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Glargine insulin | DRUG | - |
1. Inclusion Criteria 1. CFRD with fasting hyperglycemia (fasting plasma glucose ≥126 mg/dl) 1. . The diagnosis must be made at a time when the patient is in his/her basal state of health with no evidence of acute exacerbation in the preceding two months. a). Acute exacerbation ...
Glargine insulin is used for Cystic Fibrosis Related Diabetes. It is a long-acting insulin being studied in patients with this condition. The drug is currently in Phase 3 clinical development and is being developed by Sanofi.
Sanofi (ticker: SNY) is developing Glargine insulin. The drug is being studied for the treatment of Cystic Fibrosis Related Diabetes and is currently in Phase 3 clinical trials.
Glargine insulin is in Phase 3 clinical development. It is being studied for Cystic Fibrosis Related Diabetes, and one Phase 3 trial has been completed. The drug is investigational and has not been approved for this indication.
Glargine insulin has one completed Phase 3 trial, NCT00222521, titled "Insulin Glargine Vs Standard Insulin Therapy." This trial enrolled 20 participants with Cystic Fibrosis Related Diabetes in the United States, with a minimum age of 12 years.
Yes, Glargine insulin is also known as insulin glargine. The clinical trial NCT00222521 refers to the drug as insulin glargine, and it is being studied for Cystic Fibrosis Related Diabetes.